Title
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
Publication Date
2020
Journal Title
Clin Lymphoma Myeloma Leuk
Abstract
© 2020 Elsevier Inc. Ibrutinib-associated arthralgias/myalgias are a frequent adverse event that can occur late in the treatment course and are mostly grade 1 or 2. For patients with grade 1 or 2 arthralgias/myalgias, dose reductions can frequently mitigate the side effects and allow patients to continue on therapy, whereas the majority of patients with grade 3 toxicity ultimately discontinue therapy. Further study is needed to determine their pathogenesis in order to develop best practice management strategies.
Volume Number
20
Issue Number
7
Pages
438-444
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Hematology/Medical Oncology
PMID
DOI
10.1016/j.clml.2020.02.001